skip to Main Content

Epigenomic Platform Detects Early-Stage Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Bluestar Genomics has published study results in the peer-reviewed journal Nature Communications demonstrating the power of the company’s platform to detect pancreatic cancer in its early stages, addressing the unmet need of more than 60,000 patients diagnosed with the disease each year in the United States alone.

The epigenomic platform analyzes a simple blood draw and identifies the presence of pancreatic cancer in patients’ DNA circulating in their blood, enabling non-invasive, precise detection of the disease, which could lead to more timely treatment and improved patient survival. Read more . . . 


Back To Top